Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
April 12, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
April 10, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 09, 2024 12:00 ET
|
Compass Therapeutics
Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental...
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
March 21, 2024 09:00 ET
|
Compass Therapeutics
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
February 29, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
February 28, 2024 08:00 ET
|
Compass Therapeutics
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface...
Compass Therapeutics Provides Corporate Update
January 05, 2024 08:00 ET
|
Compass Therapeutics
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer...
Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023 07:30 ET
|
Compass Therapeutics
Opened 29 clinical sites and continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in patients with advanced biliary tract cancers (BTC); top...
Compass Therapeutics to Participate in Upcoming Investor Events
November 07, 2023 08:00 ET
|
Compass Therapeutics
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics to Participate in Upcoming Investor Events
August 30, 2023 08:00 ET
|
Compass Therapeutics
BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...